Posted by Michael Wonder on 29 Jul 2025
Alteogen receives positive CHMP opinion for aflibercept biosimilar, 'Eyluxvi (ALT-L9)'
28 July 2025 - Upon approval, Eyluxvi will be Alteogen's second biosimilar product, following a Herceptin biosimilar by Alteogen's license partner Qilu Pharmaceutical.
Alteogen announced today that the EMA's CHMP has adopted a positive opinion for Eyluxvi (code name: ALT-L9), a biosimilar referencing Eylea (aflibercept), co-developed with its subsidiary Alteogen Biologics.
